In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations

Anti-Cancer Drugs

Volumn 16, Issue 4, 2005, Pages 423-433

  Cheung, Richard Y ^a   Rauth, Andrew M ^b   Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Doxorubicin; In vivo efficacy; Intratumoral delivery; Microsphere; Mitomycin C; Solid tumors; Toxicity

Indexed keywords

DEXTRAN DERIVATIVE; DOXORUBICIN; MICROSPHERE; MITOMYCIN C; POLYMER; SULFOPROPYL DEXTRAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; BODY WEIGHT; BREAST SARCOMA; CALIBRATION; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; FEMALE; FLUID INTAKE; FOOD INTAKE; HEART; HISTOPATHOLOGY; IN VIVO STUDY; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; DEXTRANS; DOXORUBICIN; DRUG CARRIERS; FEMALE; HEART; INJECTIONS, INTRALESIONAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICROSPHERES; MITOMYCIN; SARCOMA, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 15944405388     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200504000-00009     Document Type: Article

References (45)

1. Boyer MJ, Tannock IF. Cellular and molecular basis of chemotherapy. In: Tannock IF, Hill RP (editors): The Basic Science of Oncology. Toronto: McGraw-Hill; 1998, pp. 350-369.
2. Fischer DS, Knobf MT, Durivage HJ. Cancer chemotherapy and pharmacology. In: The Cancer Chemotherapy Handbook. Toronto: Mosby; 1997, pp. 1-20.
3. Tannock IF, Goldenberg GJ. Drug resistance and experimental chemotherapy. In: Tannock IF, Hill RP (editors): The Basic Science of Oncology. Toronto: McGraw-Hill; 1998, pp. 392-419.
4. Powis G. A unique opportunity to study human toxicology. In: The Toxicity of Anticancer Drugs. Toronto: Pergamon Press; 1991, pp. 1-9.
5. Kellen JA. Multidrug resistance in human malignancies. In: Reversal of Multidrug Resistance in Cancer. Ann Arbor, MI: CRC Press; 1993, pp. 69-91.
6. Slingerland JM, Tannock IF. Cell proliferation and cell death. In: Tannock IF, Hill RP (editors): The Basic Science of Oncology, Toronto: McGraw-Hill; 1998, pp. 134-165.
7. Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28:S36-S41.
8. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47:3039-3051.
9. Ewesuedo RB, Ratain MJ. Principles of cancer chemotherapy. In: Vokes EE, Golomb HM (editors): Oncologic Therapies. New York: Springer; 2003, pp. 19-66.
10. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein. Trends Biochem Sci 2000; 25:1-6.
11. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22:7468-7485.
12. Anderson JH, McArdle CS, Cooke TG. Microparticulate carriers as a therapeutic option in regional cancer therapy: clinical considerations. In: Willmott N, Daly J (editors): Microspheres and Regional Cancer Therapy. Boca Raton, FL: CRC Press; 1994, pp. 57-70.
13. El-Kareh AW, Secomb TW. Theoretical models for drug delivery to solid tumors. Crit Rev Biomed Eng 1997; 25:503-571.
14. Casciari JJ, Hollingshead MG, Alley MC, Mayo JG, Malspeis L, Miyauchi S, et al. Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. J Natl Cancer Inst 1994; 86: 1846-1852.
15. Goldberg EP, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol 2002; 54:159-180.
16. Gupta PK, Hung CT, Lam FC. Applications of particulate carriers. In: Rolland A (editor): Intratumoral Drug Delivery. New York: Marcel Dekker; 1993, pp. 135-164.
17. Fournier E, Passirani C, Montero-Menei C, Colin N, Breton P, Sagodira S, et al. Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats. Cancer 2003; 97:2822-2829.
18. Almond BA, Hadba AR, Freeman ST, Cuevas BJ, York AM, Detrisac CJ, et al. Efficacy of mitoxantrone-loaded albumin microspheres for intratumoral chemotherapy of breast cancer. J Control Rel 2003; 91:147-155.
19. Emerich DF, Snodgrass P, LaFreniere D, Dean RL, Salzberg H, Marsh J, et al. Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions. Pharm Res 2002; 19:1052-1060.
20. Liu Z, Ballinger JR, Rauth AM, Bendayan R, Wu XY. Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres. J Pharm Pharmacol 2003; 55:1063-1073.
21. Liu Z, Cheung R, Wu XY, Ballinger JR, Bendayan R, Rauth AM. A study of doxorubicin loading onto and release from sulfopropyl dextran ion-exchange microspheres. J Control Rel 2001; 77:213-224.
22. Liu Z, Bendayan R, Wu XY. Triton-X-100-modified polymer and microspheres for reversal of multidrug resistance. J Pharm Pharmacol 2001; 53:1-9.
23. Liu Z, Wu XY, Ballinger JR, Bendayan R. Synthesis and characterization of surface-hydrophobic ion exchange microspheres and the effect of coating on the release rate. J Pharm Sci 2000; 89:807-817.
24. Liu Z, Wu XY, Bendayan R. In vitro investigation of ionic polysaccharide microspheres for simultaneous delivery of chemosensitizer and antineoplastic agent to multidrug-resistant cells. J Pharm Sci 1999; 88:412-418.
25. Cheung RY, Ying Y, Rauth AM, Marcon N, Wu XY. Biodegradable dextran-based microspheres for the delivery of an anticancer drug mitomycin C. Biomaterials 2005; in press.
26. Cheung RY, Kuba R, Rauth AM, Wu XY. A new approach to the in vivo and in vitro investigation of drug release from locoregionally delivered microspheres. J Control Rel 2004; 100:121-133.
27. Moore MJ, Erlichman C. Pharmacology of anticancer drugs. In: Tannock IF, Hill RP (editors): The Basic Science of Oncology. Toronto: McGraw-Hill; 1998, pp. 370-391.
28. Ilangovan G, Li H, Zweier JL, Kuppusamy P. In vivo measurement of tumor redox environment using EPR spectroscopy. Mol Cell Biochem 2002; 234-235:393-398.
29. Rockwell S, Hughes CS. Effects of mitomycin C and porfiromycin on exponentially growing and plateau phase cultures. Cell Prolif 1994; 27:153-163.
30. Cheung RY, Ronaldson P, Rauth AM, Bendayan R, Wu XY. Microsphere- delivered mitomycin C and doxorubicin and the effects on cancer cells of combining mitomycin C and doxorubicin. Submitted.
31. Rauth AM, Mohindra JK, Tannock IF. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res 1983; 43:4154-4158.
32. Andersson M, Daugaard S, von der Maase H, Mouridsen HT. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study. Cancer Treat Rep 1986; 70:1181-1186.
33. Hortobagyi GN. Mitomycin: its evolving role in the treatment of breast cancer. Oncology 1993; 50(suppl):1-8.
34. Doxorubicin monograph. In: McEvoy GK (editor): American Hospital Formulary Service. Bethesda, MD: American Society of Health System Pharmacists; 2003, pp. 971-980.
35. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk, CT: Appleton & Lange; 1994.
36. 2) on the in vivo radiation response of a murine tumor. Int J Radiat Oncol Biol Phys 1977; 2:903-911.
37. Bertazzoli C, Bellini O, Magrini U, Tosana MG. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep 1979; 63:1877-1883.
38. Idani H, Matsuoka J, Yasuda T, Kobayashi K, Tanaka N. Intra-tumoral injection of doxorubicin (adriamycin) encapsulated in liposome inhibits tumor growth, prolongs survival time and is not associated with local or systemic side effects. Int J Cancer 2000; 88:645-651.
39. Twentyman PR, Bleehan NM. The sensitivity to cytotoxic agents of the EMT6 tumour in vivo. Comparitive response of lung nodules in rapid exponential growth and of the solid flank tumor. Br J Cancer 1976; 33: 320-328.
40. Hahn GM, Braun B, Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (or bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 1975; 72:937-940.
41. Fu KC, Begg AB, Kane U, Phillips TL. Interaction of radiation and adriamycin in the EMT6 tumor as a function of tumor size and assay method. Int J Radiat Oncol Biol Phys 1979; 5:1249-1254.
42. Twentyman PR, Kallman RF, Brown JM. The effect of time between X-irradiation and chemotherapy on the growth of three solid tumors-I. Adriamycin. Int J Radiat Biol Phys 1979; 5:1255-1260.
43. Rockwell S, Kennedy KA. Combination therapy with radiation and mitomycin C: preliminary results with EMT6 tumor cells in vitro and in vivo. Int J Radiat Oncol Biol Phys 1979; 5:1673-1676.
44. Rockwell S, Nierenburg M, Irvin CG. Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio. Cancer Treat Rep 1987; 71:927-934.
45. Revesz L, Siracka E. Tumor vascularization, hypoxia, staging of tumors and radiocurability. Strahlentherapie 1984; 160:658-660.